CBD Oil for Sleep and Migraine: Trigeminovascular Activation, REM-Phase Headache, and the Bidirectional Sleep-Migraine Relationship | PureCraft CBD

CBD Oil and Migraine Medications: Drug Interaction Context — CGRP Biologics Are Interaction-Free; Triptans, Gepants, and Preventives Require Awareness

CGRP monoclonal antibodies (erenumab/Aimovig, fremanezumab/Ajovy, galcanezumab/Emgality, eptinezumab/Vyepti) — no CYP metabolism, no pharmacokinetic interaction: The CGRP monoclonal antibodies are large biological molecules metabolized through proteolytic degradation pathways entirely independent of the CYP enzyme system — the same class of interaction profile as the IBD biologics discussed in P11-228. No CBD pharmacokinetic interaction. These are the fastest-growing migraine preventive class and represent the majority of specialty migraine preventive users. The mechanistic relationship with CBD is non-redundant and potentially complementary: CGRP mAbs block CGRP signaling at the receptor (erenumab) or the CGRP ligand itself (fremanezumab, galcanezumab, eptinezumab) — downstream blockade; CBD's TRPV1 desensitization on trigeminal sensory neurons reduces the upstream release of CGRP from those neurons by desensitizing the channel whose activation triggers CGRP exocytosis. Upstream CGRP release reduction (CBD) + downstream CGRP receptor blockade (mAb) = complementary mechanism targeting at both ends of the CGRP pathway. No dose adjustment, no special monitoring. Physician awareness of CBD co-use remains appropriate at any migraine specialty appointment.

Gepant CGRP receptor antagonists (ubrogepant/Ubrelvy, rimegepant/Nurtec, atogepant/Qulipta) — CYP3A4 substrate, meaningful interaction for regular gepant use: Unlike the large biologic CGRP mAbs, the small molecule gepants are CYP3A4 substrates with significant CYP3A4-mediated metabolism. CBD's moderate CYP3A4 inhibition can elevate gepant plasma levels. For acute gepant use (ubrogepant or rimegepant taken at migraine onset, occasional use): the interaction at standard doses (50–100 mg ubrogepant, 75 mg rimegepant) and sleep-support CBD doses (15–25 mg) is generally modest. For atogepant used as a daily preventive (60 mg once daily): daily CYP3A4 inhibition from regular CBD use warrants physician discussion for dose adjustment consideration — atogepant's label already carries instructions for CYP3A4 inhibitor dose adjustment. Disclosure to the prescribing neurologist or headache specialist is appropriate for gepant users adding CBD.

Triptans (sumatriptan, rizatriptan, eletriptan, zolmitriptan) — variable CYP profiles, serotonin mechanism distinction from CBD: The triptan class are 5-HT1B/1D receptor agonists — they act on serotonin receptors, causing meningeal vasoconstriction and trigeminal pain pathway inhibition to abort migraine attacks. CBD's mechanism is 5-HT1A partial agonism — a different receptor subtype with different downstream effects (anxiolysis and autoreceptor modulation rather than meningeal vasoconstriction). The two mechanisms are not redundant or competitive; they address different aspects of the serotonergic system. CYP profiles: sumatriptan (MAO-A, not CYP — no CBD interaction); rizatriptan (MAO-A — no CBD interaction); eletriptan (CYP3A4 — modest CBD interaction, eletriptan already has a strong CYP3A4 inhibitor contraindication with ketoconazole; CBD at standard doses is not a strong CYP3A4 inhibitor, but awareness is appropriate); zolmitriptan (MAO-A/CYP1A2 — minimal CBD interaction). The combination of CBD regular use with occasional triptan acute use is generally considered acceptable in clinical practice; physician awareness at the headache specialist level is appropriate.

Traditional preventive medications (topiramate, valproate, propranolol, amitriptyline, nortriptyline) — variable CYP interactions: Topiramate (Topamax) — CYP3A4 inducer, which would slightly reduce CBD plasma levels (induction reduces CYP3A4 substrate levels); generally not a concerning direction for CBD efficacy. Valproate (Depakote) — CYP2C9/2C19 inhibitor with complex interactions; valproate and CBD interaction was studied in the Epidiolex epilepsy trials where valproate elevated CBD plasma levels; physician awareness essential for any valproate + CBD combination. Propranolol — CYP2D6 substrate; CBD's mild CYP2D6 inhibition has modest propranolol plasma level effect, additive bradycardia/hypotension consideration; same profile as the beta-blocker interaction described in the Long COVID (P11-226) and other posts. Amitriptyline/nortriptyline (TCAs) — CYP2D6/2C19; additive sedation + CYP2D6 modest; therapeutic drug monitoring appropriate.

Lasmiditan (Reyvow, 5-HT1F agonist) — CYP3A4 substrate, CNS depression additive: Lasmiditan is the newest acute migraine treatment class — a selective 5-HT1F agonist that inhibits trigeminal pain transmission without the meningeal vasoconstriction of triptans (important for patients with cardiovascular contraindications to triptans). CYP3A4 substrate; CBD interaction at sleep-support doses is modest. The more relevant caution: lasmiditan produces significant CNS depression (dizziness, sedation — the label requires no driving for eight hours after use), and additive sedation with CBD is a consideration for the night of acute lasmiditan use. Not a contraindication, but patients should be aware of additive sedation when combining lasmiditan for acute treatment with CBD on the same night.

Episodic Migraineurs on CGRP Biologics: Complementary Mechanism, Zero Interaction

For the rapidly growing population of episodic and chronic migraineurs on CGRP monoclonal antibody preventives (erenumab, fremanezumab, galcanezumab, eptinezumab — monthly or quarterly injectable) — the most important clinical context is the complete absence of pharmacokinetic interaction between CGRP mAbs and CBD, combined with the genuinely complementary mechanisms: the mAb blocks CGRP at the receptor or ligand level (downstream), while CBD's TRPV1 desensitization reduces CGRP release from trigeminal sensory neurons (upstream). For migraineurs on CGRP mAbs who still experience breakthrough attacks despite biologic therapy, CBD's upstream TRPV1 mechanism, ANS stabilization, and sleep architecture support address mechanisms that CGRP blockade does not fully cover — particularly the REM-phase trigeminovascular activation component that accounts for many early-morning breakthrough attacks. The Nano CBD Broad Spectrum Oil is the primary vehicle — sublingual delivery forty-five minutes before sleep, for the ANS parasympathetic shift into sleep onset and the 5-HT1A/HPA/FAAH mechanisms that stabilize the neurochemical environment of early sleep. The Softgels taken at sleep onset provide the overnight CB2 anti-inflammatory and TRPV1 coverage that extends through the four-to-nine AM early morning REM window — the specific timing when the early morning migraine attack risk is highest. For chronic migraineurs who find attacks consistently cluster in the morning: the softgel's sustained release through the overnight and early morning period is the key product for the REM-phase attack window. CGRP mAb users who are physician-disclosed about CBD use (as appropriate for any supplement at specialty migraine appointments) can use the full protocol without any interaction concern.

Episodic Migraineurs Focused on Sleep Regularity and Attack Prevention

For episodic migraineurs not on specialty preventive therapy — managing with triptans for acute attacks, lifestyle modification (sleep regularity, avoiding triggers), and potentially traditional preventives (topiramate, propranolol, amitriptyline) — the CBD protocol emphasis is on sleep architecture stabilization that supports the consistent sleep timing that migraine management requires. The single most clinically validated behavioral intervention for migraine prevention is consistent sleep timing — same bedtime, same wake time, seven to eight hours nightly, with minimal weekend deviation. CBD supports this goal through multiple mechanisms: the FAAH/HPA mechanism reduces the evening cortisol that delays sleep onset and pushes bedtime later; the adenosine reuptake inhibition supports appropriate sleep pressure accumulation for consistent sleep onset; the ANS parasympathetic shift reduces the sympathetic arousal that both delays sleep onset and increases early-morning REM instability; and the 5-HT1A serotonergic support stabilizes the raphe serotonin dynamics that are most volatile at the sleep-wake transition. The CBD+CBN+D9+Melatonin Gummies are particularly valuable for migraineurs whose inconsistent sleep timing is driving the weekend-trigger pattern: the melatonin component of these gummies — taken sixty to ninety minutes before target sleep onset time, including on weekends — helps anchor the circadian clock to the consistent bedtime that CGRP timing requires. Melatonin's utility for migraine sleep timing is well-documented in migraine literature: several small randomized trials have found melatonin as effective as low-dose amitriptyline for migraine prevention, likely through its circadian anchoring of the sleep-wake cycle that stabilizes the serotonin and cortisol awakening response consistency that migraine vulnerability depends on. The Nano CBD Muscle & Joint Cream for neck and temporal muscle tension: many migraineurs have significant pericranial muscle tenderness and tension that is both a migraine trigger and a consequence of attacks, and the cream's TRPV1 desensitization applied to the posterior neck, temples, and suboccipital region before sleep can reduce the peripheral sensitization input from cervical and pericranial muscles that contributes to trigeminocervical sensitization during the overnight period. This cervical muscle application of the cream is unique to migraine in the product line and represents a direct topical approach to one of the peripheral sensitization inputs that feeds early-morning trigeminovascular activation.

The Migraine Sleep Protocol: Consistency, Timing, and Early-Morning Coverage

Sleep timing consistency is the primary migraine sleep management goal: Unlike most other conditions in this series where more sleep is always better, migraine management requires precision sleep timing — same bedtime and wake time within a thirty-minute window, seven to eight hours nightly, including weekends. CBD's role is supporting the neurochemical consistency (cortisol evening stability, serotonergic regulation, adenosine pressure accumulation) that makes consistent sleep timing achievable. No CBD protocol successfully substitutes for sleep timing discipline in migraineurs.

Overnight and early-morning coverage is the highest priority: Because the four-to-nine AM REM-dense period is the peak migraine attack window, the overnight coverage provided by the softgel taken at sleep onset — extending sustained CB2 anti-inflammatory and TRPV1 modulation through the early morning — is the protocol element most specifically targeted at the sleep-migraine biology. The combination of sublingual oil at bedtime (faster onset for ANS and serotonergic stabilization in first half of night) plus softgel at sleep onset (sustained coverage through early morning) provides layered coverage across the full overnight attack risk window.

Melatonin for circadian anchoring, not just sleep onset: For weekend migraine sufferers, melatonin's role is specifically circadian — taken at the same time every night (including weekends), it anchors the sleep-onset circadian signal regardless of whether sleep actually comes at that time. This is the mechanism by which consistent melatonin timing can reduce weekend migraine triggered by delayed sleep schedules: the circadian melatonin signal remains consistent even when sleep timing drifts, reducing the hormonal volatility of irregular weekend sleep.

Cervical and pericranial cream application: Unique to migraine in this series — applying the cream to the posterior neck, temples, and suboccipital region (the muscle groups most commonly tender in migraineurs) before sleep reduces peripheral sensitization input from the cervical muscles that feed trigeminocervical sensitization during the overnight period. This is an adjunct, not a primary mechanism, but specifically relevant for migraineurs with prominent cervical muscle tenderness and tension as prodrome or trigger.

Acute attack nights: do not add CBD to triptan or lasmiditan on the same night without physician awareness: On nights when a migraine attack has been treated with a triptan or lasmiditan, CBD for sleep can still be used (the serotonergic mechanisms are at different receptor subtypes — triptans at 5-HT1B/1D, CBD at 5-HT1A), but the additive sedation concern with lasmiditan specifically warrants awareness. The post-attack sleep period is when the brain is most vulnerable to the central sensitization accumulation that follows attacks, and CBD's CB2 anti-inflammatory mechanism during post-attack sleep may actually be relevant for sensitization reduction in this window.

Can CBD oil help with migraine that wakes me up at night or starts when I wake up in the morning?

The early morning migraine — striking in the four-to-nine AM window, often beginning during the final sleep cycles and either waking you mid-sleep with an established headache or present from the first moment of waking — represents the most directly mechanistically approachable migraine pattern for CBD's sleep-related mechanisms. The reason is that early morning migraine is driven by the specific neurobiological conditions of REM-dense sleep: increased cerebral blood flow, autonomic nervous system instability during REM oscillations, reduced raphe serotonergic tone (serotonin production drops during REM), and the cortisol-serotonin transition of the waking process — all of which lower the trigeminovascular activation threshold and increase CGRP release probability from sensitized trigeminal sensory neurons. CBD's mechanisms address three of these four REM-phase vulnerabilities: ANS parasympathetic stabilization through adenosine A1 receptor engagement in brainstem autonomic nuclei (NTS/DMVN) reduces the autonomic oscillations of REM that produce meningeal vascular reactivity; TRPV1 desensitization on trigeminal sensory terminals (accumulated over weeks of consistent use) reduces the channel's probability of triggering CGRP release during the REM-associated vascular events; and 5-HT1A partial agonism supports the serotonergic circuit stability during the REM-to-waking serotonin transition. The practical protocol for early morning migraine: the softgel taken at sleep onset is the most important product — its sustained release covers the four-to-nine AM window specifically. The oil taken forty-five minutes before sleep establishes the ANS and serotonergic foundation for the first half of the night. Most migraineurs who find CBD helpful for early morning patterns describe a gradual improvement over four to eight weeks of consistent daily use — consistent with TRPV1 desensitization accumulation timescale — rather than an immediate attack prevention effect. CBD does not abort established migraine attacks. Once a migraine has initiated — once CGRP has been released and the trigeminocervical sensitization cascade is underway — CBD's mechanisms do not provide acute attack relief. The triptans or gepants prescribed for acute management remain the appropriate acute treatment. CBD's role is in the overnight period before attack initiation, reducing the probability that the REM-phase conditions trigger the CGRP cascade in the first place.

Why do I get migraines when I sleep in on weekends, and can CBD oil help?

Weekend migraine — also called "sleep-in migraine" or "Saturday morning migraine" — is one of the most commonly reported migraine patterns, and its mechanism explains both why it happens and why CBD can be part of the management approach alongside the essential behavioral intervention (consistent wake time). The mechanism: most working adults maintain a fairly consistent sleep schedule on weekdays (for example, sleeping eleven PM to six-thirty AM) and then extend their sleep on weekends (sleeping eleven PM to nine or ten AM). This extension of sleep into late morning creates several converging migraine triggers. First, the extended sleep pushes through multiple additional REM cycles — REM sleep dominates the final third of any sleep period, so sleeping until nine AM instead of six-thirty AM means two to three additional REM cycles, each with the reduced serotonin, increased cerebral blood flow, and autonomic instability that lower migraine threshold. Second, the cortisol awakening response (CAR) — the sharp cortisol rise that occurs in the forty-five minutes after waking — is delayed from six-thirty AM to nine AM, creating a prolonged pre-waking window of low cortisol (cortisol normally begins rising around forty-five minutes before habitual waking; sleeping in means cortisol doesn't start rising until much later). The low-cortisol extended-REM period is the highest migraine risk window of the twenty-four-hour cycle. Third, the delayed wake time means delayed caffeine intake for regular coffee drinkers — caffeine withdrawal over the extended sleep-in period independently triggers migraine headache through adenosine receptor super-sensitization (caffeine blocks adenosine receptors; when caffeine is withdrawn, adenosine floods the now-upregulated receptors, causing vasodilation and headache). CBD's role for weekend migraine specifically: the melatonin component of the CBN/melatonin gummies, taken at the same time every night including Friday and Saturday nights, anchors the circadian sleep-onset signal to a consistent time — and when combined with a consistent wake time (the most important single intervention for weekend migraine), the circadian anchoring maintains the hormonal consistency of the sleep-wake cycle. The behavioral intervention — keeping wake time within sixty minutes of the weekday wake time on weekends, even if bedtime is later — is the primary weekend migraine prevention strategy and cannot be substituted by CBD. But CBD's circadian support through consistent melatonin timing, HPA cortisol modulation, and 5-HT1A serotonergic stabilization all support the hormonal consistency of regular sleep timing that prevents the REM-extended, cortisol-delayed, caffeine-withdrawal convergence of weekend migraine.

Can CBD oil be used with CGRP migraine injections or gepant pills?

The CGRP pathway is now the dominant target of specialty migraine therapy, and the CBD interaction profile differs substantially between the two main CGRP drug classes — monoclonal antibodies and gepants — making the distinction important. CGRP monoclonal antibodies (erenumab/Aimovig, fremanezumab/Ajovy, galcanezumab/Emgality, eptinezumab/Vyepti): these are large biological molecules administered as monthly or quarterly injections (or quarterly IV infusion for eptinezumab), metabolized through proteolytic degradation with no involvement of the CYP enzyme system. CBD has no pharmacokinetic interaction with any of the CGRP monoclonal antibodies — no plasma level changes, no dose adjustments required. The mechanisms are genuinely complementary and non-redundant: the CGRP mAbs block CGRP signaling at the receptor (erenumab blocks the CGRP receptor) or block the CGRP ligand itself (fremanezumab, galcanezumab, eptinezumab bind CGRP and prevent it from binding its receptor). CBD's TRPV1 desensitization mechanism operates upstream of CGRP release — reducing the probability that trigeminal sensory neurons release CGRP in the first place, through desensitization of the TRPV1 calcium channel that initiates CGRP exocytosis. Upstream CGRP release prevention (CBD) combined with downstream CGRP receptor blockade (mAb) is a genuinely complementary dual-pathway approach. Gepants (ubrogepant/Ubrelvy, rimegepant/Nurtec, atogepant/Qulipta): these are small molecule CGRP receptor antagonists that are CYP3A4 substrates, and CBD's moderate CYP3A4 inhibition can modestly elevate gepant plasma levels. For occasional acute gepant use (ubrogepant or rimegepant taken only at attack onset, not daily), the interaction at typical doses is generally modest and not a primary concern. For atogepant used as a daily preventive (60 mg once daily): the daily CYP3A4 inhibition from regular CBD use warrants physician discussion, as atogepant's prescribing information already includes dose adjustment guidance for co-administration with CYP3A4 inhibitors. Disclosure to the prescribing neurologist or headache specialist about CBD use is appropriate for all gepant users. In practice, many headache specialists are becoming familiar with patients who use both CBD and CGRP-targeting therapy; a transparent conversation about the combination is more productive than avoiding disclosure.

How long does CBD oil take to help with migraine sleep problems?

The timeline for CBD's effects on migraine sleep disruption is governed by which mechanisms are producing the benefit, and understanding this distinction helps set realistic expectations for the trajectory of improvement. Fastest effects (one to two weeks): the ANS parasympathetic shift and HPA/FAAH cortisol modulation mechanisms engage relatively quickly with consistent daily use. Most migraineurs notice improvement in sleep-onset ease and in the "wired but tired" evening alertness within the first one to two weeks — the cortisol and ANS mechanisms don't require long accumulation periods to provide meaningful effect. The 5-HT1A serotonergic modulation begins sensitizing postsynaptic receptors within days to weeks of consistent use, providing the anxiolytic and serotonergic stabilizing effects that reduce the pre-sleep hyperarousal and the sleep-wake serotonin volatility. The melatonin circadian anchoring provides its effect from the first night — melatonin works as a circadian signal immediately, not cumulatively. Intermediate effects (two to four weeks): the N3 sleep architecture improvement from the CBN component and the broader sleep consolidation from the full protocol typically emerges in the second to fourth week, as the sleep architecture begins rebuilding from the fragmented pattern that migraine-related sleep disruption produces. Slowest effects (four to twelve weeks): TRPV1 desensitization on trigeminal sensory neurons — the mechanism most directly relevant to reducing early morning migraine attack probability by raising the CGRP release threshold — requires sustained CBD engagement over weeks to months to accumulate meaningful desensitization. This is the mechanism with the most direct relevance to migraine attack prevention through sleep, and it is the one that takes the longest. Migraineurs who abandon CBD after two to three weeks without noticing reduced attack frequency may be withdrawing before the TRPV1 desensitization that is the most mechanism-specific migraine-sleep effect has had time to accumulate. The CB2 anti-inflammatory reduction of the neuroinflammatory milieu that maintains lowered CSD threshold also requires consistent weeks-to-months use to reduce the chronic neuroinflammatory state that chronic poor sleep and prior attacks have established. The practical recommendation: commit to a three-month consistent daily protocol before evaluating CBD's effect on migraine frequency and early-morning attack pattern. The first month provides sleep quality improvement (the ANS, HPA, and 5-HT1A mechanisms); the second and third months build the TRPV1 desensitization and neuroinflammatory modulation that are the most migraine-specific mechanisms.

Does CBD oil interact with triptans for migraine?

Triptans remain the most widely used acute migraine treatment worldwide — sumatriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, and naratriptan — and the interaction profile with CBD varies by the specific triptan based on its metabolism pathway. The most important conceptual point: triptans are 5-HT1B/1D agonists and CBD is a 5-HT1A partial agonist — these are different serotonin receptor subtypes with different downstream mechanisms (triptans produce meningeal vasoconstriction and trigeminal pain pathway inhibition; CBD modulates raphe autoreceptor function and prefrontal/hippocampal 5-HT1A postsynaptic circuits). They do not compete at the same serotonin receptor, and the theoretical serotonin syndrome concern that exists for SSRI + triptan combinations (where both are powerfully elevating synaptic serotonin) does not apply to CBD + triptan — CBD does not produce the serotonergic agonism or reuptake inhibition magnitude that creates serotonin syndrome risk. Metabolic profiles by triptan: sumatriptan (MAO-A metabolism — no CYP, no CBD interaction); rizatriptan (MAO-A — no CYP, no CBD interaction); almotriptan (MAO-A/CYP3A4 — modest CBD interaction through CYP3A4); eletriptan (CYP3A4 — moderate interaction concern, eletriptan already has strong CYP3A4 inhibitor warnings; at standard CBD sleep-support doses the interaction is not equivalent to a strong CYP3A4 inhibitor, but physician awareness is appropriate); zolmitriptan (MAO-A/CYP1A2 — minimal CBD interaction through CYP1A2, which CBD does not significantly inhibit); frovatriptan/naratriptan (primarily renal/minimal CYP — minimal CBD interaction). For the majority of triptan users (sumatriptan and rizatriptan are the most prescribed): no pharmacokinetic interaction with CBD. For eletriptan users: appropriate to mention CBD at the headache specialist visit. In practice, CBD is typically used daily for sleep support while triptans are used acutely at attack onset — the temporal separation of use (nightly CBD vs. acute triptan only during attacks) further reduces the clinical significance of even modest pharmacokinetic interactions. The combination of nightly CBD for sleep architecture support and triptan for acute attack management is a rational combination that addresses different timepoints in the migraine cycle: prevention-supporting mechanisms (CBD overnight) and acute abort (triptan at onset).

Is there a difference between how CBD oil helps migraine sleep versus tension headache sleep?

Migraine and tension-type headache (TTH) produce distinct patterns of headache-sleep interaction, and the mechanisms through which CBD is relevant differ significantly between the two — making the distinction clinically meaningful for protocol selection. Tension-type headache sleep disruption: TTH is characterized by bilateral, pressing/tightening, non-pulsating head pain (versus migraine's typically unilateral, pulsating quality) without the nausea, photophobia, and phonophobia of migraine. The primary sleep interaction in TTH is through pericranial muscle tenderness — the chronically tender, taut pericranial muscles (temporalis, masseter, occipitalis, suboccipitalis, cervical paraspinals) that characterize chronic tension-type headache maintain peripheral nociceptive input that contributes to nocturnal pain, and the central sensitization of TTH (documented on pressure pain threshold testing, which shows widespread lowered thresholds in TTH) produces a chronic pain state that disrupts sleep through the same bidirectional pain-sleep mechanisms described in the chronic pain post (P11-207). For TTH, CBD's most relevant mechanisms are the TRPV1 desensitization and CB2 anti-inflammatory for the peripheral and central sensitization components, and the cream's topical application to pericranial muscles is particularly relevant — directly addressing the site of peripheral nociception that maintains TTH central sensitization. For migraine: the trigeminovascular CGRP mechanism, REM-phase specific timing, the sleep bidirectional paradox (both too little and too much sleep trigger attacks), and the serotonergic fluctuation mechanism at the sleep-wake boundary are all specific to migraine and not present in TTH. CBD's 5-HT1A and ANS mechanisms are far more relevant to migraine than TTH. The two conditions frequently co-exist in the same individuals (episodic TTH + episodic migraine is the most common pattern in headache specialist practices), and the CBD protocol covers the mechanisms relevant to both. The practical observation: migraineurs with a strong pericranial muscle component often have a significant TTH-mechanism overlap, and the cream applied to posterior neck and temples provides the TTH mechanism coverage while the systemic oil and softgels provide the migraine-specific mechanisms. A comprehensive protocol addresses both.

Medical Disclaimer

This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including migraine, tension-type headache, chronic daily headache, or any sleep disorder. CBD oil does not abort migraine attacks, does not block CGRP signaling, and is not a substitute for established migraine preventive or acute therapies. The statements in this article have not been evaluated by the Food and Drug Administration. Individuals with migraine should disclose CBD use to their prescribing neurologist or headache specialist, particularly those using gepants (especially atogepant as daily preventive), eletriptan, lasmiditan, or valproate. Always consult a healthcare provider before making changes to migraine management. Individual responses to CBD vary.